Ophthalmology Times - Ophthalmic News via MedWorm.com MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Ophthalmology Times - Ophthalmic News' source. Thu, 11 Mar 2010 15:33:24 +0100 Inspire initiates phase II trials with azithromycin for treatment of blepharitis http://www.medworm.com/index.php?rid=2394144&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fophthalmologytimes.modernmedicine.com%2Fophthalmologytimes%2FClinical%2BNews%2FARVO-Inspire-initiates-phase-II-trials-with-azithr%2FArticleStandard%2FArticle%2Fdetail%2F596780%3FcontextCategoryId%3D2695%26ref%3D25 Inspire Pharmaceuticals Inc. announced it has initiated two phase II clinical trials with azithromycin ophthalmic solution 1% (AzaSite) to pursue a potential indication for the treatment of blepharitis. The drug currently is approved by the FDA for the treatment of bacterial conjunctivitis. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2394144 Thu, 07 May 2009 04:00:00 +0100 2394144 Second Sight doubles patient enrollment for retinal implant study http://www.medworm.com/index.php?rid=2394146&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fophthalmologytimes.modernmedicine.com%2Fophthalmologytimes%2FOphthalmic%2BNews%2FARVO-Second-Sight-doubles-patient-enrollment-for-r%2FArticleStandard%2FArticle%2Fdetail%2F596778%3FcontextCategoryId%3D2695%26ref%3D25 Second Sight Medical Products Inc. announced that the FDA has granted approval for up to 20 people who are blind or who have severely impaired vision due to retinitis pigmentosa to participate in a feasibility study for its retinal implant (Argus II Retinal Implant) in the United States. Ten RP volunteers are participating in the U.S. study and an additional 12 RP volunteers are participating in similar studies throughout Europe and Mexico. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2394146 Wed, 06 May 2009 04:00:00 +0100 2394146 Novagali Pharma IND cleared for phase III study of cationic emulsion of latanoprost http://www.medworm.com/index.php?rid=2394145&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fophthalmologytimes.modernmedicine.com%2Fophthalmologytimes%2FClinical%2BNews%2FARVO-Novagali-Pharma-IND-cleared-for-phase-III-stu%2FArticleStandard%2FArticle%2Fdetail%2F596779%3FcontextCategoryId%3D2695%26ref%3D25 Novagali Pharma announced that the company's investigational new drug application to conduct a phase III clinical trial of Nova21027 (Catioprost), a cationic emulsion of latanoprost for the treatment of glaucoma, has been granted by the FDA. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2394145 Wed, 06 May 2009 04:00:00 +0100 2394145 Wilmer Eye Institute breaks ground on new, upgraded facility http://www.medworm.com/index.php?rid=943432&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FWilmer-Eye-Institute-breaks-ground-on-new-upgraded%2FArticleStandard%2FArticle%2Fdetail%2F443738%3FcontextCategoryId%3D2695%26ref%3D25 The Wilmer Eye Institute of Johns Hopkins University School of Med-icine opened a $100 million, privately funded, 207,000-square-foot facility that will build on the current research and clinical space for its 130 full-time faculty (90 clinician scientists; 40 PhD researchers). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=943432 Thu, 11 Oct 2007 04:00:00 +0100 943432 Wilmer Eye Institute breaks ground on new, upgraded facility http://www.medworm.com/index.php?rid=823814&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%3A80%2Fophthalmologytimes%2FOphthalmic%2BNews%2FWilmer-Eye-Institute-breaks-ground-on-new-upgraded%2FArticleStandard%2FArticle%2Fdetail%2F443738%3FcontextCategoryId%3D2695%26ref%3D25 The Wilmer Eye Institute of Johns Hopkins University School of Med-icine opened a $100 million, privately funded, 207,000-square-foot facility that will build on the current research and clinical space for its 130 full-time faculty (90 clinician scientists; 40 PhD researchers). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=823814 Mon, 27 Aug 2007 04:00:00 +0100 823814 Wilmer Eye Institute breaks ground on new, upgraded facility http://www.medworm.com/index.php?rid=757045&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D443738%26ref%3D25 The Wilmer Eye Institute of Johns Hopkins University School of Med-icine opened a $100 million, privately funded, 207,000-square-foot facility that will build on the current research and clinical space for its 130 full-time faculty (90 clinician scientists; 40 PhD researchers). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=757045 Wed, 25 Jul 2007 04:00:00 +0100 757045 Photochromic IOL to be available in Europe http://www.medworm.com/index.php?rid=745787&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D439334%26ref%3D25 S (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=745787 Fri, 20 Jul 2007 04:00:00 +0100 745787 FDA OKs azithromycin 1% ophthalmic solution http://www.medworm.com/index.php?rid=718278&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D435735%26ref%3D25 S (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=718278 Sat, 07 Jul 2007 04:00:00 +0100 718278 Bepotastine promising against ocular itching http://www.medworm.com/index.php?rid=699693&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D435734%26ref%3D25 S (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=699693 Thu, 28 Jun 2007 02:09:03 +0100 699693 Bausch & Lomb to merge with private equity firm http://www.medworm.com/index.php?rid=697350&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D435730%26ref%3D25 S (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=697350 Wed, 27 Jun 2007 02:08:25 +0100 697350 ASCRS launches ectasia registry http://www.medworm.com/index.php?rid=695581&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D435733%26ref%3D25 S (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=695581 Tue, 26 Jun 2007 04:00:00 +0100 695581 Texas centers ready to help restore sight http://www.medworm.com/index.php?rid=689022&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D418296%26ref%3D25 Boca Raton, FL—Nova Vision Inc. has installed its device (Vision Restoration Therapy [VRT]) in two centers in Texas, where therapists can help restore sight to people who have been left partially blind by a stroke or brain injury. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=689022 Fri, 22 Jun 2007 04:00:00 +0100 689022 Dr. Campbell joins Sophrona advisory board http://www.medworm.com/index.php?rid=684250&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D418289%26ref%3D25 Minneapolis—Robert C. Campbell, MD, has joined the advisory board of Sophrona Solutions. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=684250 Thu, 21 Jun 2007 04:00:00 +0100 684250 The price of vision http://www.medworm.com/index.php?rid=2519273&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FThe-price-of-vision%2FArticleStandard%2FArticle%2Fdetail%2F439331%3FcontextCategoryId%3D2695%26ref%3D25 Chicago?The aggregate cost related to adult vision conditions in the United States has climbed to an estimated $51.4 billion, according to a pioneering report from Prevent Blindness America (PBA). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519273 Thu, 14 Jun 2007 23:00:00 +0100 2519273 Cyclosporine A tested for dry eye http://www.medworm.com/index.php?rid=2519272&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FCyclosporine-A-tested-for-dry-eye%2FArticleStandard%2FArticle%2Fdetail%2F439338%3FcontextCategoryId%3D2695%26ref%3D25 Tampa, FL?Two companies are researching cyclosporine A as a potential treatment for dry eye syndrome. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519272 Thu, 14 Jun 2007 23:00:00 +0100 2519272 Trials begin on drop to heal ocular wounds http://www.medworm.com/index.php?rid=2519271&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FTrials-begin-on-drop-to-heal-ocular-wounds%2FArticleStandard%2FArticle%2Fdetail%2F439339%3FcontextCategoryId%3D2695%26ref%3D25 Bethesda, MD?The FDA will allow Regene-Rx Biopharmaceuticals Inc. to begin a phase II trial of its Thymosin beta 4 (TB4) for the treatment of diabetic patients undergoing vitrectomy surgery. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519271 Thu, 14 Jun 2007 23:00:00 +0100 2519271 AMO recalls lens solution http://www.medworm.com/index.php?rid=2519270&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FAMO-recalls-lens-solution%2FArticleStandard%2FArticle%2Fdetail%2F439328%3FcontextCategoryId%3D2695%26ref%3D25 In response to reports received from the Centers for Disease Control and Prevention (CDC) regarding eye infections from Acanthamoeba, Advanced Medical Optics (AMO) has voluntarily recalled its Complete MoisturePlus contact lens solutions. No evidence suggests that the voluntary recall is related to a product contamination issue, according to AMO. The company is working with the CDC, FDA, and others to ensure that consumers are aware of the need for proper contact lens disinfection and proper lens handling. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519270 Thu, 14 Jun 2007 23:00:00 +0100 2519270 Spreading agent introduced to market http://www.medworm.com/index.php?rid=2519269&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FSpreading-agent-introduced-to-market%2FArticleStandard%2FArticle%2Fdetail%2F439335%3FcontextCategoryId%3D2695%26ref%3D25 San Diego?Baxter Healthcare Corp. has launched its hyaluronidase human injection (Hylenex recombinant) for use in enhancing the absorption and dispersion of injected ophthalmic anesthetics. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519269 Thu, 14 Jun 2007 23:00:00 +0100 2519269 Photochromic IOL to be available in Europe http://www.medworm.com/index.php?rid=2519268&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FPhotochromic-IOL-to-be-available-in-Europe%2FArticleStandard%2FArticle%2Fdetail%2F439334%3FcontextCategoryId%3D2695%26ref%3D25 Irvine, CA?Medennium Inc. expects that its photochromic IOL (Aurium) will be available in all European countries by September now that it has obtained CE mark clearance to market the lens. It is the first and only photochromic IOL, according to the company. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519268 Thu, 14 Jun 2007 23:00:00 +0100 2519268 Therapy improves visual field defect http://www.medworm.com/index.php?rid=2519267&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FTherapy-improves-visual-field-defect%2FArticleStandard%2FArticle%2Fdetail%2F439336%3FcontextCategoryId%3D2695%26ref%3D25 Boston--More than 70% of stroke and traumatic brain injury (TBI) survivors with homonymous visual-field defects demonstrated a visual field improvement of more than 3% following a six-module course of vision restoration therapy, according to a study released by NovaVision. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519267 Thu, 14 Jun 2007 23:00:00 +0100 2519267 AMO phaco system offers dual-pump fluidics http://www.medworm.com/index.php?rid=2519266&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FAMO-phaco-system-offers-dual-pump-fluidics%2FArticleStandard%2FArticle%2Fdetail%2F439333%3FcontextCategoryId%3D2695%26ref%3D25 San Diego?Advanced Medical Optics (AMO) Inc. has introduced a new phacoemulsification system featuring dual-pump fluidics (WhiteStar Signature with Fusion). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519266 Thu, 14 Jun 2007 23:00:00 +0100 2519266 Trials to test efficacy of ocular implants http://www.medworm.com/index.php?rid=2519265&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FTrials-to-test-efficacy-of-ocular-implants%2FArticleStandard%2FArticle%2Fdetail%2F439337%3FcontextCategoryId%3D2695%26ref%3D25 Lincoln, RI?Biotechnology firm Neurotech Pharmaceuticals Inc. has begun two phase II/III clinical trials with NT-501, the company's lead Encapsulated Cell Technology (ECT) product for the treatment of visual loss associated with retinitis pigmentosa. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519265 Thu, 14 Jun 2007 23:00:00 +0100 2519265 Six researchers win $100,000 grants http://www.medworm.com/index.php?rid=661719&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D418294%26ref%3D25 Fort Worth, TX—The Alcon Research Institute (ARI) has given six ocular researchers $100,000 each to further their research endeavors. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=661719 Thu, 14 Jun 2007 04:00:00 +0100 661719 Bepotastine promising against ocular itching http://www.medworm.com/index.php?rid=2519277&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FBepotastine-promising-against-ocular-itching%2FArticleStandard%2FArticle%2Fdetail%2F435734%3FcontextCategoryId%3D2695%26ref%3D25 Preliminary phase II/III results of a clinical trial of bepotastine for the treatment of allergic conjunctivitis show statistically significant results against some symptoms, according to ISTA Pharmaceuticals Inc. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519277 Thu, 31 May 2007 23:00:00 +0100 2519277 ASCRS launches ectasia registry http://www.medworm.com/index.php?rid=2519276&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FIndustry%2BNews%2FASCRS-launches-ectasia-registry%2FArticleStandard%2FArticle%2Fdetail%2F435733%3FcontextCategoryId%3D2695%26ref%3D25 The American Society of Cataract and Refractive Surgery (ASCRS) has launched the ASCRS International Ectasia Registry as part of a two-phase project to define ectasia more precisely, determine its frequency, and identify risk factors. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519276 Thu, 31 May 2007 23:00:00 +0100 2519276 FDA OKs azithromycin 1% ophthalmic solution http://www.medworm.com/index.php?rid=2519275&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FFDA-OKs-azithromycin-1-ophthalmic-solution%2FArticleStandard%2FArticle%2Fdetail%2F435735%3FcontextCategoryId%3D2695%26ref%3D25 InSite Vision Inc. expects its azithromycin 1% ophthalmic solution (Aza- Site) to be launched commercially in the United States in the second half of this year now that the FDA has approved the company's new drug application. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519275 Thu, 31 May 2007 23:00:00 +0100 2519275 Bausch & Lomb to merge with private equity firm http://www.medworm.com/index.php?rid=2519274&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FBausch-amp-Lomb-to-merge-with-private-equity-firm%2FArticleStandard%2FArticle%2Fdetail%2F435730%3FcontextCategoryId%3D2695%26ref%3D25 After more than 150 years in business (69 of them as a public company), Bausch & Lomb has accepted an offer to merge with Warburg Pincus, a private equity firm. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519274 Thu, 31 May 2007 23:00:00 +0100 2519274 Horizontal tightening of upper eyelid helps with floppy eyelid syndrome http://www.medworm.com/index.php?rid=2519278&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FPlastics%2FHorizontal-tightening-of-upper-eyelid-helps-with-f%2FArticleStandard%2FArticle%2Fdetail%2F434925%3FcontextCategoryId%3D2695%26ref%3D25 Horizontal eyelid tightening alone results in secondary improvement in the ptosis associated with floppy eyelid syndrome, according to the results of a case series in 24 eyelids of 18 patients. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519278 Mon, 14 May 2007 23:00:00 +0100 2519278 Robert Osher, MD, treasures his Charles Kelman Award presented by Hellenic Society http://www.medworm.com/index.php?rid=2519287&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FRobert-Osher-MD-treasures-his-Charles-Kelman-Award%2FArticleStandard%2FArticle%2Fdetail%2F435760%3FcontextCategoryId%3D2695%26ref%3D25 Robert H. Osher, MD, has received numerous accolades over his lifetime as an innovative surgeon, video producer, athletic coach, professor, and medical director of a large practice. But, he said, the Charles Kelman Award he received recently from the Hellenic Society of Intraocular Implant & Refractive Surgery is among his most treasured. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519287 Mon, 30 Apr 2007 23:00:00 +0100 2519287 $4.75 million grant to fund stem-cell work http://www.medworm.com/index.php?rid=2519286&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2F475-million-grant-to-fund-stem-cell-work%2FArticleStandard%2FArticle%2Fdetail%2F435764%3FcontextCategoryId%3D2695%26ref%3D25 The Lincy Foundation has given the first installment of a 4-year, $4.75 million grant to the Oregon Retinal Degeneration Center at Oregon Health & Science (OHSU) Casey Eye Institute. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519286 Mon, 30 Apr 2007 23:00:00 +0100 2519286 Phase II trial to study DME http://www.medworm.com/index.php?rid=2519285&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FPhase-II-trial-to-study-DME%2FArticleStandard%2FArticle%2Fdetail%2F435763%3FcontextCategoryId%3D2695%26ref%3D25 The Juvenile Diabetes Research Foundation (JDRF) is enrolling patients in a study to test the long-term safety and effectiveness of intraocular injections of ranibizumab (Lucentis, Genentech) in patients with diabetic macular edema (DME) (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519285 Mon, 30 Apr 2007 23:00:00 +0100 2519285 Accommodating IOL leads revenue surge http://www.medworm.com/index.php?rid=2519284&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FAccommodating-IOL-leads-revenue-surge%2FArticleStandard%2FArticle%2Fdetail%2F435765%3FcontextCategoryId%3D2695%26ref%3D25 Aliso Viejo, CA—First-quarter 2007 revenues for eyeonics inc., the developer of the crystalens accommodating IOL, have increased 36% over the same period last year, the company said. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519284 Mon, 30 Apr 2007 23:00:00 +0100 2519284 CDC examines apparent Acanthamoeba keratitis outbreak http://www.medworm.com/index.php?rid=2519283&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FCDC-examines-apparent-Acanthamoeba-keratitis-outbr%2FArticleStandard%2FArticle%2Fdetail%2F435759%3FcontextCategoryId%3D2695%26ref%3D25 Ophthalmologists and epidemiologists around the country are growing concerned about an apparent increase in the number of Acanthamoeba keratitis cases they are seeing. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519283 Mon, 30 Apr 2007 23:00:00 +0100 2519283 Protective eye gear essential for modern soldier http://www.medworm.com/index.php?rid=2519282&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FProtective-eye-gear-essential-for-modern-soldier%2FArticleStandard%2FArticle%2Fdetail%2F435761%3FcontextCategoryId%3D2695%26ref%3D25 Preventing ocular injuries during war by using protective devices may reduce the incidence of these injuries, which currently hold the number four slot for highest incidence after amputation, traumatic brain injury, and post-traumatic stress disorder. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519282 Mon, 30 Apr 2007 23:00:00 +0100 2519282 Iridex settles with Synergetics http://www.medworm.com/index.php?rid=2519281&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FIridex-settles-with-Synergetics%2FArticleStandard%2FArticle%2Fdetail%2F435767%3FcontextCategoryId%3D2695%26ref%3D25 S (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519281 Mon, 30 Apr 2007 23:00:00 +0100 2519281 State policies reviewed at first 'Vision Summit' http://www.medworm.com/index.php?rid=2519280&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FState-policies-reviewed-at-first-Vision-Summit%2FArticleStandard%2FArticle%2Fdetail%2F435766%3FcontextCategoryId%3D2695%26ref%3D25 Vision health advocates convened here to review data and the effectiveness of various state policy models to provide children's vision care in what is touted as the first "Vision Summit." (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519280 Mon, 30 Apr 2007 23:00:00 +0100 2519280 Generic drug sale blocked until 2009 http://www.medworm.com/index.php?rid=2519279&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FGeneric-drug-sale-blocked-until-2009%2FArticleStandard%2FArticle%2Fdetail%2F435762%3FcontextCategoryId%3D2695%26ref%3D25 A federal appellate court has blocked the largest Canadian-owned pharmaceutical company from manufacturing and selling a generic version of Allergan's ketorolac tromethamine ophthalmic solution 0.5% (Acular). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519279 Mon, 30 Apr 2007 23:00:00 +0100 2519279 NicOx, Pfizer announce phase II trial of latanoprost derivative http://www.medworm.com/index.php?rid=2519301&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FNicOx-Pfizer-announce-phase-II-trial-of-latanopros%2FArticleStandard%2FArticle%2Fdetail%2F435339%3FcontextCategoryId%3D2695%26ref%3D25 NicOx and Pfizer will initiate a phase II, dose-finding study of its PF-03187207 compound for the treatment of patients with glaucoma and ocular hypertension. The 28-day trial is designed to compare the safety and efficacy of the drug with that of latanoprost (Xalatan, Pfizer Ophthalmics). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519301 Sat, 14 Apr 2007 23:00:00 +0100 2519301 Ophthonix picks Osbaldeston as chief executive officer http://www.medworm.com/index.php?rid=2519300&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FOphthonix-picks-Osbaldeston-as-chief-executive-off%2FArticleStandard%2FArticle%2Fdetail%2F435443%3FcontextCategoryId%3D2695%26ref%3D25 Ophthonix has named Stephen J. Osbaldeston as its chief executive officer. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519300 Sat, 14 Apr 2007 23:00:00 +0100 2519300 Anti-VEGF peptide near phase I clinical trials http://www.medworm.com/index.php?rid=2519299&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FAnti-VEGF-peptide-near-phase-I-clinical-trials%2FArticleStandard%2FArticle%2Fdetail%2F435343%3FcontextCategoryId%3D2695%26ref%3D25 Potentia Pharmaceuticals said it would initiate phase I clinical trials to evaluate its drug POT-4, for the treatment of age-related macular degeneration (AMD). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519299 Sat, 14 Apr 2007 23:00:00 +0100 2519299 Topigen Pharmaceuticals, Novagali Pharma to collaborate on drug-delivery system http://www.medworm.com/index.php?rid=2519298&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FTopigen-Pharmaceuticals-Novagali-Pharma-to-collabo%2FArticleStandard%2FArticle%2Fdetail%2F435342%3FcontextCategoryId%3D2695%26ref%3D25 Topigen Pharmaceuticals and Novagali Pharma will collaborate on products designed to improve the bioadhesion and efficacy of RNA-targeting therapeutics delivered to the nasal membrane and ocular surface. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519298 Sat, 14 Apr 2007 23:00:00 +0100 2519298 Newly formed Opko Corp. plans to study wet AMD therapy http://www.medworm.com/index.php?rid=2519297&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FNewly-formed-Opko-Corp-plans-to-study-wet-AMD-ther%2FArticleStandard%2FArticle%2Fdetail%2F435341%3FcontextCategoryId%3D2695%26ref%3D25 Newly formed Opko Corp. plans a phase III trial of bevasiranib (formerly Cand5) as maintenance therapy for wet AMD in combination with ranibizumab (Lucentis, Genentech). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519297 Sat, 14 Apr 2007 23:00:00 +0100 2519297 Bausch & Lomb earns NTIOL status for two lens products http://www.medworm.com/index.php?rid=2519296&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FBausch-amp-Lomb-earns-NTIOL-status-for-two-lens-pr%2FArticleStandard%2FArticle%2Fdetail%2F435337%3FcontextCategoryId%3D2695%26ref%3D25 Bausch & Lomb has earned NTIOL status for its SofPort Advanced Optics and SofPort Advanced Optics with Violet Shield lenses. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519296 Sat, 14 Apr 2007 23:00:00 +0100 2519296 Ostrov joins NuLens board of directors http://www.medworm.com/index.php?rid=2519295&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FOstrov-joins-NuLens-board-of-directors%2FArticleStandard%2FArticle%2Fdetail%2F435346%3FcontextCategoryId%3D2695%26ref%3D25 NuLens has named Gerald M. Ostrov to its board of directors. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519295 Sat, 14 Apr 2007 23:00:00 +0100 2519295 Ophthalmology Times wins two 2007 Neal Awards for editorial excellence http://www.medworm.com/index.php?rid=2519294&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FIndustry%2BNews%2FOphthalmology-Times-wins-two-2007-Neal-Awards-for-%2FArticleStandard%2FArticle%2Fdetail%2F435332%3FcontextCategoryId%3D2695%26ref%3D25 Ophthalmology Times magazine earned two awards in the 53rd annual Jesse H. Neal National Business Journalism Awards competition recognizing editorial excellence. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519294 Sat, 14 Apr 2007 23:00:00 +0100 2519294 Iridex, Synergetics square off to settle patent dispute http://www.medworm.com/index.php?rid=2519293&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FIridex-Synergetics-square-off-to-settle-patent-dis%2FArticleStandard%2FArticle%2Fdetail%2F435442%3FcontextCategoryId%3D2695%26ref%3D25 Iridex Corp. and Synergetics USA Inc. are headed to trial to settle a patent dispute. Iridex claims that Synergetics relied on its patented technology to create a connector for handheld probes it sold between 1999 and mid-2006. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519293 Sat, 14 Apr 2007 23:00:00 +0100 2519293 Dr. Osher to sign copies of his books for children at ASCRS meeting http://www.medworm.com/index.php?rid=2519292&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FDr-Osher-to-sign-copies-of-his-books-for-children-%2FArticleStandard%2FArticle%2Fdetail%2F435344%3FcontextCategoryId%3D2695%26ref%3D25 Robert H. Osher, MD, carves time out of his professional, academic, and personal responsibilities to write books for children. He will sign copies of seven of his titles during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519292 Sat, 14 Apr 2007 23:00:00 +0100 2519292 Dr. Singh appointed editor of British Journal of Ophthalmology (USA) http://www.medworm.com/index.php?rid=2519291&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FDr-Singh-appointed-editor-of-British-Journal-of-Op%2FArticleStandard%2FArticle%2Fdetail%2F435347%3FcontextCategoryId%3D2695%26ref%3D25 Arun D. Singh, MD, has been named editor of the British Journal of Ophthalmology (USA). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519291 Sat, 14 Apr 2007 23:00:00 +0100 2519291 Carl Zeiss Vision announces Howard as new president http://www.medworm.com/index.php?rid=2519290&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FCarl-Zeiss-Vision-announces-Howard-as-new-presiden%2FArticleStandard%2FArticle%2Fdetail%2F435345%3FcontextCategoryId%3D2695%26ref%3D25 Frederick Howard has been named the new president and general manager, Americas, for Carl Zeiss Vision. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519290 Sat, 14 Apr 2007 23:00:00 +0100 2519290 VEGF drug improves vision in patients with wet AMD http://www.medworm.com/index.php?rid=2519289&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FVEGF-drug-improves-vision-in-patients-with-wet-AMD%2FArticleStandard%2FArticle%2Fdetail%2F435340%3FcontextCategoryId%3D2695%26ref%3D25 Based on a planned, interim analysis of a phase II randomized study, Regeneron Pharmaceuticals and Bayer HealthCare said patients with wet age-related macular degeneration (AMD) who received just one dose of their vascular endothelial growth factor (VEGF) drug (Trap-Eye) maintained or improved vision at 12 weeks. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519289 Sat, 14 Apr 2007 23:00:00 +0100 2519289 Ziemer Group to take on sales, marketing of keratome http://www.medworm.com/index.php?rid=2519288&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FZiemer-Group-to-take-on-sales-marketing-of-keratom%2FArticleStandard%2FArticle%2Fdetail%2F435338%3FcontextCategoryId%3D2695%26ref%3D25 Ziemer Group will take on the worldwide sales, marketing, and support activities for an automated microkeratome (Amadeus II) and all related accessories and consumables. The product line is engineered and manufactured by a Ziemer Group company, SIS Surgical Instrument Systems Ltd. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519288 Sat, 14 Apr 2007 23:00:00 +0100 2519288 Extra review delays lens approval http://www.medworm.com/index.php?rid=2519310&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FExtra-review-delays-lens-approval%2FArticleStandard%2FArticle%2Fdetail%2F418292%3FcontextCategoryId%3D2695%26ref%3D25 Monrovia, CA—STAAR Surgical Co. says the application for its toric phakic implantable IOL (Visian TICL) will be submitted to the Ophthalmic Devices Panel of the FDA's Center for Devices and Radiological Health for evaluation, delaying the approval it had hoped would come later this year. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519310 Sat, 31 Mar 2007 23:00:00 +0100 2519310 Texas centers ready to help restore sight http://www.medworm.com/index.php?rid=2519309&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FTexas-centers-ready-to-help-restore-sight%2FArticleStandard%2FArticle%2Fdetail%2F418296%3FcontextCategoryId%3D2695%26ref%3D25 Boca Raton, FL—Nova Vision Inc. has installed its device (Vision Restoration Therapy [VRT]) in two centers in Texas, where therapists can help restore sight to people who have been left partially blind by a stroke or brain injury. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519309 Sat, 31 Mar 2007 23:00:00 +0100 2519309 Dr. Khurana receives AMA Foundation award http://www.medworm.com/index.php?rid=2519308&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FDr-Khurana-receives-AMA-Foundation-award%2FArticleStandard%2FArticle%2Fdetail%2F418290%3FcontextCategoryId%3D2695%26ref%3D25 Washington, DC—Rahul N. Khurana, MD, from Santa Monica, CA, has been named a recipient of the American Medical Association (AMA) Foundation's 2007 Leadership Award. This award provides medical students, residents/fellows, young physicians, and international medical graduate physicians from around the country with special training to develop their skills as future leaders in organized medicine. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519308 Sat, 31 Mar 2007 23:00:00 +0100 2519308 Inspire agrees to sell InSite anti-infective http://www.medworm.com/index.php?rid=2519307&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FInspire-agrees-to-sell-InSite-anti-infective%2FArticleStandard%2FArticle%2Fdetail%2F418293%3FcontextCategoryId%3D2695%26ref%3D25 Alameda, CA—Inspire Pharmaceuticals plans to commercialize InSite Vision Inc.'s topical anti-infective for treating bacterial conjunctivitis (AzaSite). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519307 Sat, 31 Mar 2007 23:00:00 +0100 2519307 Range expands for accommodating IOL http://www.medworm.com/index.php?rid=2519306&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FRange-expands-for-accommodating-IOL%2FArticleStandard%2FArticle%2Fdetail%2F418295%3FcontextCategoryId%3D2695%26ref%3D25 Aliso Viejo, CA—eyeonics Inc. has expanded the range of its accommodating lens (crystalens Five-O) to benefit patients with larger eyes and more precise diopter needs. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519306 Sat, 31 Mar 2007 23:00:00 +0100 2519306 Dr. Campbell joins Sophrona advisory board http://www.medworm.com/index.php?rid=2519305&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FDr-Campbell-joins-Sophrona-advisory-board%2FArticleStandard%2FArticle%2Fdetail%2F418289%3FcontextCategoryId%3D2695%26ref%3D25 Minneapolis—Robert C. Campbell, MD, has joined the advisory board of Sophrona Solutions. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519305 Sat, 31 Mar 2007 23:00:00 +0100 2519305 Six researchers win $100,000 grants http://www.medworm.com/index.php?rid=2519304&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FSix-researchers-win-100000-grants%2FArticleStandard%2FArticle%2Fdetail%2F418294%3FcontextCategoryId%3D2695%26ref%3D25 Fort Worth, TX—The Alcon Research Institute (ARI) has given six ocular researchers $100,000 each to further their research endeavors. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519304 Sat, 31 Mar 2007 23:00:00 +0100 2519304 B&L recalls second contact lens solution http://www.medworm.com/index.php?rid=2519303&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FBampL-recalls-second-contact-lens-solution%2FArticleStandard%2FArticle%2Fdetail%2F418288%3FcontextCategoryId%3D2695%26ref%3D25 Rochester, NY—Bausch & Lomb is voluntarily recalling about 1.5 million bottles of its contact lens solution (ReNu MultiPlus) after it discovered elevated levels of trace iron had caused some of the solution to discolor and lose effectiveness. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519303 Sat, 31 Mar 2007 23:00:00 +0100 2519303 University of Iowa launches Project 3000 http://www.medworm.com/index.php?rid=2519302&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FUniversity-of-Iowa-launches-Project-3000%2FArticleStandard%2FArticle%2Fdetail%2F418291%3FcontextCategoryId%3D2695%26ref%3D25 Iowa City, IA—The University of Iowa is launching Project 3000 in an effort to identify all 3,000 U.S. men, women, and children who have Leber's congenital amaurosis (LCA). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519302 Sat, 31 Mar 2007 23:00:00 +0100 2519302 Ranibizumab approved for use in Europe http://www.medworm.com/index.php?rid=574277&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D417521%26ref%3D25 Basel, Switzerland—The European Union has approved ranibizumab (Lucentis, Genentech) as a new treatment for patients with wet age-related macular degeneration (AMD). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=574277 Thu, 15 Mar 2007 04:00:00 +0100 574277 Latanoprost derivatives show help for glaucoma http://www.medworm.com/index.php?rid=574276&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D417612%26ref%3D25 Sophia Antipolis, France—Nitric oxide-donating derivatives of latanoprost (Xalatan) are showing an improved ability to lower IOP for the treatment of glaucoma, according to preclinical results of research conducted by NicOx SA and Pfizer Inc. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=574276 Thu, 15 Mar 2007 04:00:00 +0100 574276 Spanish, Portuguese translations offered at Wilmer meeting http://www.medworm.com/index.php?rid=574275&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D417610%26ref%3D25 Baltimore—Wilmer Eye Institute's Current Concepts in Ophthalmology meeting here in April promises a uniquely international flair because it will be presented in English with simultaneous translations into Spanish and Portuguese. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=574275 Thu, 15 Mar 2007 04:00:00 +0100 574275 Once-daily drug as safe as original formula http://www.medworm.com/index.php?rid=574274&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D417611%26ref%3D25 Lrvine, CA—ISTA Pharmaceuticals Inc. said its bromfenac sodium ophthalmic solution (Xibrom) once-daily formulation produced highly statistically significant results in its phase III clinical trials. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=574274 Thu, 15 Mar 2007 04:00:00 +0100 574274 Dr. Whitman elected president of ACES http://www.medworm.com/index.php?rid=574273&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D417609%26ref%3D25 Dallas—The American College of Eye Surgeons (ACES) has named Jeffrey Whitman, MD, president of the national organization for a 2-year term. Dr. Whitman is medical director and chief surgeon of Dallas-based Key-Whitman Eye Center and has been practicing ophthalmic surgery for more than 20 years. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=574273 Thu, 15 Mar 2007 04:00:00 +0100 574273 Study: patients with poor vision incur greater medical costs http://www.medworm.com/index.php?rid=574272&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D417606%26ref%3D25 Baltimore—The impact of poor vision costs Medicare more than $2 billion each year for non-eye-care-related concerns, prompting a call by some to put further emphasis on vision health for all Americans. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=574272 Thu, 15 Mar 2007 04:00:00 +0100 574272 OXiGENE appoints Kollins to business development post http://www.medworm.com/index.php?rid=574271&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D417608%26ref%3D25 Waltham, MA—OXiGENE Inc., a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, announced that John A. Kollins has joined the company as senior vice president and chief business officer. In the latter role, Kollins will be responsible for all business development activities as well as commercial strategy for the company. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=574271 Thu, 15 Mar 2007 04:00:00 +0100 574271 Ophthalmology Times is a finalist for "Pulitzer Prize of business press" http://www.medworm.com/index.php?rid=574269&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D417607%26ref%3D25 Cleveland—Ophthalmology Times magazine has been named a finalist in the 53rd annual Jesse H. Neal National Business Awards competition recognizing editorial excellence. The awards, which have been called the Pulitzer Prizes of the business press, are sponsored by American Business Media, an association of business information providers. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=574269 Thu, 15 Mar 2007 04:00:00 +0100 574269 Wet AMD treatment approved in Europe http://www.medworm.com/index.php?rid=2519320&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FWet-AMD-treatment-approved-in-Europe%2FArticleStandard%2FArticle%2Fdetail%2F417614%3FcontextCategoryId%3D2695%26ref%3D25 Toronto—Novadaq Technologies said the European Union has approved the OPTTX System, a minimally invasive treatment for wet age-related macular degeneration. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519320 Thu, 15 Mar 2007 00:00:00 +0100 2519320 Latanoprost derivatives show help for glaucoma http://www.medworm.com/index.php?rid=2519319&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FLatanoprost-derivatives-show-help-for-glaucoma%2FArticleStandard%2FArticle%2Fdetail%2F417612%3FcontextCategoryId%3D2695%26ref%3D25 Sophia Antipolis, France—Nitric oxide-donating derivatives of latanoprost (Xalatan) are showing an improved ability to lower IOP for the treatment of glaucoma, according to preclinical results of research conducted by NicOx SA and Pfizer Inc. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519319 Thu, 15 Mar 2007 00:00:00 +0100 2519319 Vision care bill touted on Capitol Hill http://www.medworm.com/index.php?rid=2519318&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FVision-care-bill-touted-on-Capitol-Hill%2FArticleStandard%2FArticle%2Fdetail%2F417613%3FcontextCategoryId%3D2695%26ref%3D25 Washington, DC—Vision advocates met with more than 60 participants of a recent congressional briefing and press conference to raise awareness about a vision-care bill for children. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519318 Thu, 15 Mar 2007 00:00:00 +0100 2519318 Once-daily drug as safe as original formula http://www.medworm.com/index.php?rid=2519317&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FOnce-daily-drug-as-safe-as-original-formula%2FArticleStandard%2FArticle%2Fdetail%2F417611%3FcontextCategoryId%3D2695%26ref%3D25 Lrvine, CA—ISTA Pharmaceuticals Inc. said its bromfenac sodium ophthalmic solution (Xibrom) once-daily formulation produced highly statistically significant results in its phase III clinical trials. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519317 Thu, 15 Mar 2007 00:00:00 +0100 2519317 Dr. Whitman elected president of ACES http://www.medworm.com/index.php?rid=2519316&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FDr-Whitman-elected-president-of-ACES%2FArticleStandard%2FArticle%2Fdetail%2F417609%3FcontextCategoryId%3D2695%26ref%3D25 Dallas—The American College of Eye Surgeons (ACES) has named Jeffrey Whitman, MD, president of the national organization for a 2-year term. Dr. Whitman is medical director and chief surgeon of Dallas-based Key-Whitman Eye Center and has been practicing ophthalmic surgery for more than 20 years. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519316 Thu, 15 Mar 2007 00:00:00 +0100 2519316 Ophthalmology Times is a finalist for 'Pulitzer Prize of business press' http://www.medworm.com/index.php?rid=2519315&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FOphthalmology-Times-is-a-finalist-for-Pulitzer-Pri%2FArticleStandard%2FArticle%2Fdetail%2F417607%3FcontextCategoryId%3D2695%26ref%3D25 Cleveland—Ophthalmology Times magazine has been named a finalist in the 53rd annual Jesse H. Neal National Business Awards competition recognizing editorial excellence. The awards, which have been called the Pulitzer Prizes of the business press, are sponsored by American Business Media, an association of business information providers. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519315 Thu, 15 Mar 2007 00:00:00 +0100 2519315 Spanish, Portuguese translations offered at Wilmer meeting http://www.medworm.com/index.php?rid=2519314&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FSpanish-Portuguese-translations-offered-at-Wilmer-%2FArticleStandard%2FArticle%2Fdetail%2F417610%3FcontextCategoryId%3D2695%26ref%3D25 Baltimore—Wilmer Eye Institute's Current Concepts in Ophthalmology meeting here in April promises a uniquely international flair because it will be presented in English with simultaneous translations into Spanish and Portuguese. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519314 Thu, 15 Mar 2007 00:00:00 +0100 2519314 Study: patients with poor vision incur greater medical costs http://www.medworm.com/index.php?rid=2519313&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FStudy-patients-with-poor-vision-incur-greater-medi%2FArticleStandard%2FArticle%2Fdetail%2F417606%3FcontextCategoryId%3D2695%26ref%3D25 Baltimore—The impact of poor vision costs Medicare more than $2 billion each year for non-eye-care-related concerns, prompting a call by some to put further emphasis on vision health for all Americans. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519313 Thu, 15 Mar 2007 00:00:00 +0100 2519313 OXiGENE appoints Kollins to business development post http://www.medworm.com/index.php?rid=2519312&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FOXiGENE-appoints-Kollins-to-business-development-p%2FArticleStandard%2FArticle%2Fdetail%2F417608%3FcontextCategoryId%3D2695%26ref%3D25 Waltham, MA—OXiGENE Inc., a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, announced that John A. Kollins has joined the company as senior vice president and chief business officer. In the latter role, Kollins will be responsible for all business development activities as well as commercial strategy for the company. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519312 Thu, 15 Mar 2007 00:00:00 +0100 2519312 Ranibizumab approved for use in Europe http://www.medworm.com/index.php?rid=2519311&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FRanibizumab-approved-for-use-in-Europe%2FArticleStandard%2FArticle%2Fdetail%2F417521%3FcontextCategoryId%3D2695%26ref%3D25 Basel, Switzerland—The European Union has approved ranibizumab (Lucentis, Genentech) as a new treatment for patients with wet age-related macular degeneration (AMD). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519311 Thu, 15 Mar 2007 00:00:00 +0100 2519311 DME drug to begin phase I trial this year http://www.medworm.com/index.php?rid=2519336&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FDME-drug-to-begin-phase-I-trial-this-year%2FArticleStandard%2FArticle%2Fdetail%2F410633%3FcontextCategoryId%3D2695%26ref%3D25 Vancouver—iCo Therapeutics Inc. said the FDA has accepted an investigational new drug application for iCo-007 to treat diabetic macular edema (DME). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519336 Thu, 01 Mar 2007 00:00:00 +0100 2519336 Dr. Sutphin joins University of Kansas medical faculty http://www.medworm.com/index.php?rid=2519335&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FDr-Sutphin-joins-University-of-Kansas-medical-facu%2FArticleStandard%2FArticle%2Fdetail%2F410625%3FcontextCategoryId%3D2695%26ref%3D25 Kansas City, KS—John E. Sutphin Jr., MD, an expert in cornea and transplant and refractive surgery, has joined the faculty of the University of Kansas School of Medicine as professor and chairman of the ophthalmology department. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519335 Thu, 01 Mar 2007 00:00:00 +0100 2519335 Vail meeting an annual tradition for Wilmer institute http://www.medworm.com/index.php?rid=2519334&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FVail-meeting-an-annual-tradition-for-Wilmer-instit%2FArticleStandard%2FArticle%2Fdetail%2F410628%3FcontextCategoryId%3D2695%26ref%3D25 Vail, CO—The Wilmer Ophthalmological Institute at Johns Hopkins University School of Medicine will host its 24th annual Current Concepts in Ophthalmology meeting here March 11 to 16. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519334 Thu, 01 Mar 2007 00:00:00 +0100 2519334 Developing global research collaborations a priority for India http://www.medworm.com/index.php?rid=2519333&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FDeveloping-global-research-collaborations-a-priori%2FArticleStandard%2FArticle%2Fdetail%2F410638%3FcontextCategoryId%3D2695%26ref%3D25 Las Vegas—India is now considered a model in the development of international research collaborations in the field of ophthalmology. Its success is based on the ability of individuals to cooperate through mutual respect, transparency, humor, and friendship, said R.D. Thulasiraj, MBA, here at the American Academy of Ophthalmology annual meeting held in conjunction with the Association for Research in Vision and Ophthalmology. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519333 Thu, 01 Mar 2007 00:00:00 +0100 2519333 Akorn seeks approval for ocular anesthetic http://www.medworm.com/index.php?rid=2519332&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FAkorn-seeks-approval-for-ocular-anesthetic%2FArticleStandard%2FArticle%2Fdetail%2F410631%3FcontextCategoryId%3D2695%26ref%3D25 Buffalo Grove, IL—Akorn Inc.'s ocular anesthetic (AK-1015 [now named Akten]) has met its endpoints in a phase III trial. The four-arm, randomized, placebo-controlled trial tested three different doses. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519332 Thu, 01 Mar 2007 00:00:00 +0100 2519332 Corneal implant made for severe keratoconus http://www.medworm.com/index.php?rid=2519331&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FCorneal-implant-made-for-severe-keratoconus%2FArticleStandard%2FArticle%2Fdetail%2F410637%3FcontextCategoryId%3D2695%26ref%3D25 Des Plaines, IL—Addition Technology Inc. has completed the first worldwide shipment of its corneal implant (Intacs SK) for patients with severe keratoconus. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519331 Thu, 01 Mar 2007 00:00:00 +0100 2519331 Pfizer, MediVas team for ophthalmic drug delivery http://www.medworm.com/index.php?rid=2519330&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FPfizer-MediVas-team-for-ophthalmic-drug-delivery%2FArticleStandard%2FArticle%2Fdetail%2F410634%3FcontextCategoryId%3D2695%26ref%3D25 New York—Pfizer Inc. and MediVas LLC have inked a collaborative agreement to research and develop advanced delivery methods for Pfizer compounds treating ophthalmic diseases. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519330 Thu, 01 Mar 2007 00:00:00 +0100 2519330 Medicare patients now have access to toric IOLs http://www.medworm.com/index.php?rid=2519329&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FMedicare-patients-now-have-access-to-toric-IOLs%2FArticleStandard%2FArticle%2Fdetail%2F410629%3FcontextCategoryId%3D2695%26ref%3D25 Washington, DC—A Jan. 22 ruling by the Centers for Medicare and Medicaid Services (CMS) gives Medicare beneficiaries undergoing cataract surgery the option to have a toric IOL implanted. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519329 Thu, 01 Mar 2007 00:00:00 +0100 2519329 Duke spin-off firm wins FDA marketing approval http://www.medworm.com/index.php?rid=2519328&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FDuke-spin-off-firm-wins-FDA-marketing-approval%2FArticleStandard%2FArticle%2Fdetail%2F410630%3FcontextCategoryId%3D2695%26ref%3D25 Research Triangle Park, NC—The FDA has approved marketing to begin for a new, non-invasive eye scanner developed by a company spun off from Duke University's biomedical engineering department. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519328 Thu, 01 Mar 2007 00:00:00 +0100 2519328 Dr. Coca-Prados serves as visiting professor http://www.medworm.com/index.php?rid=2519327&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FDr-Coca-Prados-serves-as-visiting-professor%2FArticleStandard%2FArticle%2Fdetail%2F410626%3FcontextCategoryId%3D2695%26ref%3D25 New Haven, CT—Glaucoma researcher Miguel Coca-Prados, PhD, recently has completed a professorship at Pfizer's Groton Laboratories as the 2006 Yale-Pfizer Global Discovery Visiting Professor. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519327 Thu, 01 Mar 2007 00:00:00 +0100 2519327 Dr. Peli receives Lighthouse's 2006 Pisart Award http://www.medworm.com/index.php?rid=2519326&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FDr-Peli-receives-Lighthouses-2006-Pisart-Award%2FArticleStandard%2FArticle%2Fdetail%2F410627%3FcontextCategoryId%3D2695%26ref%3D25 New York—Lighthouse International has bestowed its 2006 Pisart Award on Eliezer (Eli) Peli, MSc, OD, professor of ophthalmology, Harvard Medical School, and the Moakley Scholar in Aging Eye Research, Schepens Eye Research Institute, Boston. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519326 Thu, 01 Mar 2007 00:00:00 +0100 2519326 Dr. Tasman to step down at Wills Eye, Jefferson http://www.medworm.com/index.php?rid=2519325&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmology%2FDr-Tasman-to-step-down-at-Wills-Eye-Jefferson%2FArticleStandard%2FArticle%2Fdetail%2F408522%3FcontextCategoryId%3D2695%26ref%3D25 Philadelphia—William S. Tasman, MD, is preparing to step down from his positions as ophthalmologist-in-chief at the Wills Eye Institute and chairman of the Department of Ophthalmology at Jefferson Medical College of Thomas Jefferson University here. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519325 Thu, 01 Mar 2007 00:00:00 +0100 2519325 Deformable mirror yields clearer view of retina http://www.medworm.com/index.php?rid=2519324&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FDeformable-mirror-yields-clearer-view-of-retina%2FArticleStandard%2FArticle%2Fdetail%2F410635%3FcontextCategoryId%3D2695%26ref%3D25 Watertown, MA—Boston Micromachines Corp., which provides MEMS-based deformable mirror products for adaptive optics systems, has created an enhanced deformable mirror for ultra-high-resolution retinal imaging. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519324 Thu, 01 Mar 2007 00:00:00 +0100 2519324 Alcon revamps Web site, access to resources http://www.medworm.com/index.php?rid=2519323&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FAlcon-revamps-Web-site-access-to-resources%2FArticleStandard%2FArticle%2Fdetail%2F410632%3FcontextCategoryId%3D2695%26ref%3D25 Fort Worth, TX—Alcon Laboratories has redesigned its Web site to deliver online eye health information more easily to physicians, patients, and their families. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519323 Thu, 01 Mar 2007 00:00:00 +0100 2519323 Genentech letter warns of stroke risk with ranibizumab http://www.medworm.com/index.php?rid=2519322&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FGenentech-letter-warns-of-stroke-risk-with-ranibiz%2FArticleStandard%2FArticle%2Fdetail%2F410624%3FcontextCategoryId%3D2695%26ref%3D25 South San Francisco—Genentech Inc. is advising ophthalmologists that it is seeing a slightly higher incidence of stroke among patients using the 0.5-mg dose of its ranibizumab injection (Lucentis) to treat wet age-related macular degeneration (AMD). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519322 Thu, 01 Mar 2007 00:00:00 +0100 2519322 Phase III trials begin for steroid compound http://www.medworm.com/index.php?rid=2519321&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FPhase-III-trials-begin-for-steroid-compound%2FArticleStandard%2FArticle%2Fdetail%2F410636%3FcontextCategoryId%3D2695%26ref%3D25 Tampa—Sirion Therapeutics Inc. has begun enrolling patients in two phase III clinical trials to evaluate difluprednate (ST-601), a steroid compound to treat inflammation after ocular surgery. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519321 Thu, 01 Mar 2007 00:00:00 +0100 2519321 Allergan donates $1M for research fellows http://www.medworm.com/index.php?rid=457341&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405962%26ref%3D25 Irvine, CA—Allergan will donate $1 million over 2 years to academic medical institutions to support fellows researching glaucoma and corneal and retinal diseases. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457341 Thu, 15 Feb 2007 05:00:00 +0100 457341 Visiogen continues study of dual-optic IOL http://www.medworm.com/index.php?rid=457340&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405958%26ref%3D25 Irvine, CA—Visiogen Inc. says it has received FDA approval to expand its phase III U.S. clinical trial for its dual-optic accommodating IOL (Synchrony). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457340 Thu, 15 Feb 2007 05:00:00 +0100 457340 Sodium hyaluronate compound studied http://www.medworm.com/index.php?rid=457339&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405959%26ref%3D25 Chapel Hill, NC—Lantibio Inc. and TRB Chemedica have begun a phase III clinical trial with VISMED, a patented formulation containing sodium hyaluronate, to treat dry eye syndrome. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457339 Thu, 15 Feb 2007 05:00:00 +0100 457339 Orphan status given to two drugs http://www.medworm.com/index.php?rid=457338&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405960%26ref%3D25 Jersey City, NJ—The FDA has granted orphan drug designation to two investigational therapeutics of Lux Biosciences, a privately held biotechnical company specializing in treatments for ophthalmic diseases. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457338 Thu, 15 Feb 2007 05:00:00 +0100 457338 IRIDEX gets patents for Laserscope aesthetics http://www.medworm.com/index.php?rid=457337&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405955%26ref%3D25 Mountain View, CA—IRIDEX Corp. has completed its acquisition of San Jose, CA-based Laserscope's aesthetics business. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457337 Thu, 15 Feb 2007 05:00:00 +0100 457337 Genaera drops plan for wet AMD drug http://www.medworm.com/index.php?rid=457336&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405957%26ref%3D25 Plymouth Meeting, PA—Genaera Corp. has decided to terminate its clinical development program for squalamine lactate (Evizon) for the treatment of wet age-related macular degeneration (AMD) after a comprehensive review of its portfolio and market conditions. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457336 Thu, 15 Feb 2007 05:00:00 +0100 457336 Gel could treat viral eye infection http://www.medworm.com/index.php?rid=457335&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405961%26ref%3D25 Tampa—Sirion Therapeutics Inc. has made an exclusive licensing agreement with Laboratoires Thea of France for U.S. rights to develop and market a topical ophthalmic gel containing ganciclovir for treating certain viral and superficial eye infections. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457335 Thu, 15 Feb 2007 05:00:00 +0100 457335 Eye firms win as best places to work http://www.medworm.com/index.php?rid=457334&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405956%26ref%3D25 New York—Genentech Inc. and Alcon Laboratories Inc. have once again made the Fortune magazine top 100 list of best companies for which to work. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457334 Thu, 15 Feb 2007 05:00:00 +0100 457334 Antihistamine acquired from Alimera Sciences http://www.medworm.com/index.php?rid=457333&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405954%26ref%3D25 Rochester, NY—Bausch & Lomb has purchased Alimera Sciences' over-the-counter allergy franchise, including ketotifen fumarate ophthalmic solution 0.025% (Alaway), which was recently approved by the FDA. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457333 Thu, 15 Feb 2007 05:00:00 +0100 457333 B&L shows interest in corneal device http://www.medworm.com/index.php?rid=457332&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405953%26ref%3D25 Rochester, NY—Bausch & Lomb has made an equity investment in—and secured an exclusive option to purchase—AcuFocus Inc., a developer of corneal inlay technology for treating presbyopia. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457332 Thu, 15 Feb 2007 05:00:00 +0100 457332 Register early to save review fees http://www.medworm.com/index.php?rid=457331&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405952%26ref%3D25 San Francisco—Ophthalmologists preparing for the 2007 American Board of Ophthalmology Demonstration of Ophthalmic Cognitive Knowledge examination can save money by registering for a review course before April 19. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457331 Thu, 15 Feb 2007 05:00:00 +0100 457331 FDA seeks answers before approving drug http://www.medworm.com/index.php?rid=457330&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405951%26ref%3D25 Irvine, CA—Allergan Inc. is continuing to evaluate a clinical study of its brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5% (Combigan) in an effort to address FDA questions prior to final marketing approval. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457330 Thu, 15 Feb 2007 05:00:00 +0100 457330 Bill would fund vision care for kids http://www.medworm.com/index.php?rid=457329&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405950%26ref%3D25 Washington, DC—A bipartisan group of federal legislators has introduced a bill in the House and Senate designed to provide follow-up care for children with identified potential vision problems. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457329 Thu, 15 Feb 2007 05:00:00 +0100 457329 Optos names new chief executive officer http://www.medworm.com/index.php?rid=457328&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405947%26ref%3D25 Dunfermline, U.K.—Optos plc has appointed Thomas W. Butts as chief executive officer and a member of the board of directors. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457328 Thu, 15 Feb 2007 05:00:00 +0100 457328 Isis appoints Dr. Jonas as executive vice president http://www.medworm.com/index.php?rid=457327&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405948%26ref%3D25 Carlsbad, CA—Jeffrey M. Jonas, MD, joined Isis Pharmaceuticals Inc. Feb. 1 as executive vice president. He will lead clinical development, preclinical development, regulatory affairs, quality assurance, and compliance at the company. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457327 Thu, 15 Feb 2007 05:00:00 +0100 457327 Farzad Yaghouti, MD, voted 'Best LASIK Surgeon 2006' http://www.medworm.com/index.php?rid=457325&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405949%26ref%3D25 San Diego—Farzad Yaghouti, MD, chief refractive surgeon at Global Laser Vision San Diego, won the 2006 (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457325 Thu, 15 Feb 2007 05:00:00 +0100 457325 Dr. Kameen and family aid Baltimore program http://www.medworm.com/index.php?rid=457323&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405946%26ref%3D25 Baltimore—Anthony J. Kameen, MD, and his family received a proclamation from outgoing Maryland Gov. Robert L. Ehrlich as a tribute to their involvement with the Helping Up Mission of Baltimore. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457323 Thu, 15 Feb 2007 05:00:00 +0100 457323 Be an advocate for surgery by surgeons, urges physician http://www.medworm.com/index.php?rid=457321&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D405945%26ref%3D25 Las Vegas—Ophthalmologists have made great headway in the past year to ensure that surgery remains with surgeons, specifically in Oklahoma, where optometrists' efforts have been thwarted. Ophthalmologists, however, must continue this vigilance. One way to do so is by contributing to the American Academy of Ophthalmology (AAO) Surgical Scope Fund, according to Randolph Johnston, MD, the AAO's senior secretary for advocacy. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=457321 Thu, 15 Feb 2007 05:00:00 +0100 457321 Visiogen continues study of dual-optic IOL http://www.medworm.com/index.php?rid=2519354&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FVisiogen-continues-study-of-dual-optic-IOL%2FArticleStandard%2FArticle%2Fdetail%2F405958%3FcontextCategoryId%3D2695%26ref%3D25 Irvine, CA—Visiogen Inc. says it has received FDA approval to expand its phase III U.S. clinical trial for its dual-optic accommodating IOL (Synchrony). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519354 Thu, 15 Feb 2007 00:00:00 +0100 2519354 Isis appoints Dr. Jonas as executive vice president http://www.medworm.com/index.php?rid=2519353&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FIsis-appoints-Dr-Jonas-as-executive-vice-president%2FArticleStandard%2FArticle%2Fdetail%2F405948%3FcontextCategoryId%3D2695%26ref%3D25 Carlsbad, CA—Jeffrey M. Jonas, MD, joined Isis Pharmaceuticals Inc. Feb. 1 as executive vice president. He will lead clinical development, preclinical development, regulatory affairs, quality assurance, and compliance at the company. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519353 Thu, 15 Feb 2007 00:00:00 +0100 2519353 FDA seeks answers before approving drug http://www.medworm.com/index.php?rid=2519352&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FFDA-seeks-answers-before-approving-drug%2FArticleStandard%2FArticle%2Fdetail%2F405951%3FcontextCategoryId%3D2695%26ref%3D25 Irvine, CA—Allergan Inc. is continuing to evaluate a clinical study of its brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5% (Combigan) in an effort to address FDA questions prior to final marketing approval. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519352 Thu, 15 Feb 2007 00:00:00 +0100 2519352 Eye firms win as best places to work http://www.medworm.com/index.php?rid=2519351&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FEye-firms-win-as-best-places-to-work%2FArticleStandard%2FArticle%2Fdetail%2F405956%3FcontextCategoryId%3D2695%26ref%3D25 New York—Genentech Inc. and Alcon Laboratories Inc. have once again made the Fortune magazine top 100 list of best companies for which to work. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519351 Thu, 15 Feb 2007 00:00:00 +0100 2519351 Farzad Yaghouti, MD, voted 'Best LASIK Surgeon 2006' http://www.medworm.com/index.php?rid=2519350&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FFarzad-Yaghouti-MD-voted-Best-LASIK-Surgeon-2006%2FArticleStandard%2FArticle%2Fdetail%2F405949%3FcontextCategoryId%3D2695%26ref%3D25 San Diego—Farzad Yaghouti, MD, chief refractive surgeon at Global Laser Vision San Diego, won the 2006 (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519350 Thu, 15 Feb 2007 00:00:00 +0100 2519350 Gel could treat viral eye infection http://www.medworm.com/index.php?rid=2519349&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FGel-could-treat-viral-eye-infection%2FArticleStandard%2FArticle%2Fdetail%2F405961%3FcontextCategoryId%3D2695%26ref%3D25 Tampa—Sirion Therapeutics Inc. has made an exclusive licensing agreement with Laboratoires Thea of France for U.S. rights to develop and market a topical ophthalmic gel containing ganciclovir for treating certain viral and superficial eye infections. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519349 Thu, 15 Feb 2007 00:00:00 +0100 2519349 Antihistamine acquired from Alimera Sciences http://www.medworm.com/index.php?rid=2519348&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FAntihistamine-acquired-from-Alimera-Sciences%2FArticleStandard%2FArticle%2Fdetail%2F405954%3FcontextCategoryId%3D2695%26ref%3D25 Rochester, NY—Bausch & Lomb has purchased Alimera Sciences' over-the-counter allergy franchise, including ketotifen fumarate ophthalmic solution 0.025% (Alaway), which was recently approved by the FDA. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519348 Thu, 15 Feb 2007 00:00:00 +0100 2519348 B&L shows interest in corneal device http://www.medworm.com/index.php?rid=2519347&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FCornea%2FBampL-shows-interest-in-corneal-device%2FArticleStandard%2FArticle%2Fdetail%2F405953%3FcontextCategoryId%3D2695%26ref%3D25 Rochester, NY—Bausch & Lomb has made an equity investment in—and secured an exclusive option to purchase—AcuFocus Inc., a developer of corneal inlay technology for treating presbyopia. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519347 Thu, 15 Feb 2007 00:00:00 +0100 2519347 Bill would fund vision care for kids http://www.medworm.com/index.php?rid=2519346&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FBill-would-fund-vision-care-for-kids%2FArticleStandard%2FArticle%2Fdetail%2F405950%3FcontextCategoryId%3D2695%26ref%3D25 Washington, DC—A bipartisan group of federal legislators has introduced a bill in the House and Senate designed to provide follow-up care for children with identified potential vision problems. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519346 Thu, 15 Feb 2007 00:00:00 +0100 2519346 Genaera drops plan for wet AMD drug http://www.medworm.com/index.php?rid=2519345&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FGenaera-drops-plan-for-wet-AMD-drug%2FArticleStandard%2FArticle%2Fdetail%2F405957%3FcontextCategoryId%3D2695%26ref%3D25 Plymouth Meeting, PA—Genaera Corp. has decided to terminate its clinical development program for squalamine lactate (Evizon) for the treatment of wet age-related macular degeneration (AMD) after a comprehensive review of its portfolio and market conditions. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519345 Thu, 15 Feb 2007 00:00:00 +0100 2519345 Orphan status given to two drugs http://www.medworm.com/index.php?rid=2519344&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FOrphan-status-given-to-two-drugs%2FArticleStandard%2FArticle%2Fdetail%2F405960%3FcontextCategoryId%3D2695%26ref%3D25 Jersey City, NJ—The FDA has granted orphan drug designation to two investigational therapeutics of Lux Biosciences, a privately held biotechnical company specializing in treatments for ophthalmic diseases. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519344 Thu, 15 Feb 2007 00:00:00 +0100 2519344 IRIDEX gets patents for Laserscope aesthetics http://www.medworm.com/index.php?rid=2519343&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FIRIDEX-gets-patents-for-Laserscope-aesthetics%2FArticleStandard%2FArticle%2Fdetail%2F405955%3FcontextCategoryId%3D2695%26ref%3D25 Mountain View, CA—IRIDEX Corp. has completed its acquisition of San Jose, CA-based Laserscope's aesthetics business. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519343 Thu, 15 Feb 2007 00:00:00 +0100 2519343 Register early to save review fees http://www.medworm.com/index.php?rid=2519342&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FRegister-early-to-save-review-fees%2FArticleStandard%2FArticle%2Fdetail%2F405952%3FcontextCategoryId%3D2695%26ref%3D25 San Francisco—Ophthalmologists preparing for the 2007 American Board of Ophthalmology Demonstration of Ophthalmic Cognitive Knowledge examination can save money by registering for a review course before April 19. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519342 Thu, 15 Feb 2007 00:00:00 +0100 2519342 Sodium hyaluronate compound studied http://www.medworm.com/index.php?rid=2519341&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FSodium-hyaluronate-compound-studied%2FArticleStandard%2FArticle%2Fdetail%2F405959%3FcontextCategoryId%3D2695%26ref%3D25 Chapel Hill, NC—Lantibio Inc. and TRB Chemedica have begun a phase III clinical trial with VISMED, a patented formulation containing sodium hyaluronate, to treat dry eye syndrome. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519341 Thu, 15 Feb 2007 00:00:00 +0100 2519341 Dr. Kameen and family aid Baltimore program http://www.medworm.com/index.php?rid=2519340&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FDr-Kameen-and-family-aid-Baltimore-program%2FArticleStandard%2FArticle%2Fdetail%2F405946%3FcontextCategoryId%3D2695%26ref%3D25 Baltimore—Anthony J. Kameen, MD, and his family received a proclamation from outgoing Maryland Gov. Robert L. Ehrlich as a tribute to their involvement with the Helping Up Mission of Baltimore. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519340 Thu, 15 Feb 2007 00:00:00 +0100 2519340 Viewpoint: Be an advocate for surgery by surgeons, urges physician http://www.medworm.com/index.php?rid=2519339&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FViewpoint-Be-an-advocate-for-surgery-by-surgeons-u%2FArticleStandard%2FArticle%2Fdetail%2F405945%3FcontextCategoryId%3D2695%26ref%3D25 Las Vegas—Ophthalmologists have made great headway in the past year to ensure that surgery remains with surgeons, specifically in Oklahoma, where optometrists' efforts have been thwarted. Ophthalmologists, however, must continue this vigilance. One way to do so is by contributing to the American Academy of Ophthalmology (AAO) Surgical Scope Fund, according to Randolph Johnston, MD, the AAO's senior secretary for advocacy. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519339 Thu, 15 Feb 2007 00:00:00 +0100 2519339 Allergan donates $1M for research fellows http://www.medworm.com/index.php?rid=2519338&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FAllergan-donates-1M-for-research-fellows%2FArticleStandard%2FArticle%2Fdetail%2F405962%3FcontextCategoryId%3D2695%26ref%3D25 Irvine, CA—Allergan will donate $1 million over 2 years to academic medical institutions to support fellows researching glaucoma and corneal and retinal diseases. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519338 Thu, 15 Feb 2007 00:00:00 +0100 2519338 Optos names new chief executive officer http://www.medworm.com/index.php?rid=2519337&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FOptos-names-new-chief-executive-officer%2FArticleStandard%2FArticle%2Fdetail%2F405947%3FcontextCategoryId%3D2695%26ref%3D25 Dunfermline, U.K.—Optos plc has appointed Thomas W. Butts as chief executive officer and a member of the board of directors. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519337 Thu, 15 Feb 2007 00:00:00 +0100 2519337 Geneticist, retinal expert joins Jules Stein Eye Institute http://www.medworm.com/index.php?rid=405317&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D401152%26ref%3D25 Los Angeles—The Jules Stein Eye Institute (JSEI) and the Department of Ophthalmology of the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), have appointed Michael Gorin, MD, the Harold and Pauline Price Chair in Ophthalmology and professor of ophthalmology in the retina and vision science divisions. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=405317 Thu, 01 Feb 2007 07:00:00 +0100 405317 B&L to undergo management changes in Americas region http://www.medworm.com/index.php?rid=405316&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D401153%26ref%3D25 Rochester, NY—Bausch & Lomb (B&L) will undergo a realignment of management responsibilities for its Americas region. The changes follow the announcement by Paul G. Howes, currently senior vice president and president-Americas Region, that he intends to resign from the company. Howes will remain with the company to effect an orderly transition to the new management structure. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=405316 Thu, 01 Feb 2007 07:00:00 +0100 405316 AMO acquires WaveFront Sciences http://www.medworm.com/index.php?rid=405315&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D401151%26ref%3D25 Santa Ana, CA—In a move designed to boost its quest for the "custom all-laser LASIK," Advanced Medical Optics (AMO) has acquired WaveFront Sciences, Albuquerque, NM, for about $20 million. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=405315 Thu, 01 Feb 2007 07:00:00 +0100 405315 AMO acquires WaveFront Sciences http://www.medworm.com/index.php?rid=2519357&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FNews%2FAMO-acquires-WaveFront-Sciences%2FArticleStandard%2FArticle%2Fdetail%2F401151%3FcontextCategoryId%3D2695%26ref%3D25 Santa Ana, CA—In a move designed to boost its quest for the "custom all-laser LASIK," Advanced Medical Optics (AMO) has acquired WaveFront Sciences, Albuquerque, NM, for about $20 million. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519357 Thu, 01 Feb 2007 00:00:00 +0100 2519357 Geneticist, retinal expert joins Jules Stein Eye Institute http://www.medworm.com/index.php?rid=2519356&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FGeneticist-retinal-expert-joins-Jules-Stein-Eye-In%2FArticleStandard%2FArticle%2Fdetail%2F401152%3FcontextCategoryId%3D2695%26ref%3D25 Los Angeles—The Jules Stein Eye Institute (JSEI) and the Department of Ophthalmology of the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), have appointed Michael Gorin, MD, the Harold and Pauline Price Chair in Ophthalmology and professor of ophthalmology in the retina and vision science divisions. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519356 Thu, 01 Feb 2007 00:00:00 +0100 2519356 B&L to undergo management changes in Americas region http://www.medworm.com/index.php?rid=2519355&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FBampL-to-undergo-management-changes-in-Americas-re%2FArticleStandard%2FArticle%2Fdetail%2F401153%3FcontextCategoryId%3D2695%26ref%3D25 Rochester, NY—Bausch & Lomb (B&L) will undergo a realignment of management responsibilities for its Americas region. The changes follow the announcement by Paul G. Howes, currently senior vice president and president-Americas Region, that he intends to resign from the company. Howes will remain with the company to effect an orderly transition to the new management structure. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2519355 Thu, 01 Feb 2007 00:00:00 +0100 2519355 Dr. James Tsai oversees department at Yale http://www.medworm.com/index.php?rid=359743&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D398680%26ref%3D25 New Haven, CT—Glaucoma specialist James C. Tsai, MD, MBA, has been named chairman of the Yale School of Medicine's Department of Ophthalmology and Visual Science. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=359743 Mon, 15 Jan 2007 07:00:00 +0100 359743 Registry will collect corneal ectasia data http://www.medworm.com/index.php?rid=359742&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D398678%26ref%3D25 Malvern, PA—DSG Inc., a provider of electronic data capture software for clinical trials, and Clinical Research Consultants Inc. (CRC) are hosting the International Ectasia Registry to facilitate the collection of data about corneal ectasia. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=359742 Mon, 15 Jan 2007 07:00:00 +0100 359742 OCT aids transplant tissue evaluation http://www.medworm.com/index.php?rid=359741&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D398675%26ref%3D25 Dublin, CA—Carl Zeiss Meditec is donating a Visante OCT to the National Eye Bank Center for evaluating corneal tissue for transplant surgery. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=359741 Mon, 15 Jan 2007 07:00:00 +0100 359741 Novel AMD drug being tested on 15 patients http://www.medworm.com/index.php?rid=359740&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D398676%26ref%3D25 Redwood City, CA—The first of 15 patients has received CGC-11047, a novel poly-amine analog that targets choroidal neovascularization associated with age-related macular degeneration. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=359740 Mon, 15 Jan 2007 07:00:00 +0100 359740 Laser manufacturers announce mergers http://www.medworm.com/index.php?rid=359739&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D398674%26ref%3D25 Adelaide, Australia—Ellex Medical Lasers Ltd., which designs and manufactures ophthalmic laser systems, has acquired Innovative Imaging Inc., a manufacturer of ophthalmic diagnostic ultrasound systems. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=359739 Mon, 15 Jan 2007 07:00:00 +0100 359739 Eye drop could prevent blood vessel growth http://www.medworm.com/index.php?rid=359738&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D398677%26ref%3D25 Roanoke, VA—OcuCure Therapeutics Inc. has received $1.5 million in seed financing to develop a topical eye drop for wet age-related macular degeneration (AMD) and dry AMD prophylaxis. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=359738 Mon, 15 Jan 2007 07:00:00 +0100 359738 Clinical trial under way for topical AMD therapy http://www.medworm.com/index.php?rid=359737&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D398679%26ref%3D25 San Diego—TargeGen has begun a phase I trial of a topical drug to treat age-related macular degeneration (AMD). (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=359737 Mon, 15 Jan 2007 07:00:00 +0100 359737 Conjunctival PAM uncommon but important disease http://www.medworm.com/index.php?rid=359736&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D398673%26ref%3D25 Las Vegas—Primary acquired melanosis (PAM) of the conjunctiva is an uncommon but important disease. Although some studies have suggested that it occurs in as much as one-third of the population, most cases do not need treatment. The disease is potentially malignant, however, and arguments can be made for early treatment if risk factors are present, said Jerry A. Shields, MD, in his delivery of the Lorenz E. Zimmerman Lecture here at a combined meeting of the American Academy of Ophthalmology and the American Association of Ocular Pathologists. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=359736 Mon, 15 Jan 2007 07:00:00 +0100 359736 AMO acquires IntraLase http://www.medworm.com/index.php?rid=359735&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.ophthalmologytimes.com%2Fophthalmologytimes%2Farticle%2FarticleDetail.jsp%3Fid%3D398671%26ref%3D25 The acquisition of IntraLase Corp. by Advanced Medical Optics (AMO), announced Jan. 9, joins two of the strongest performers in the refractive surgery market. The $808 million cash transaction may be the impetus for a change in how the traditional microkeratome is viewed among refractive surgeons. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=359735 Mon, 15 Jan 2007 07:00:00 +0100 359735 OCT aids transplant tissue evaluation http://www.medworm.com/index.php?rid=3157121&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FOCT-aids-transplant-tissue-evaluation%2FArticleStandard%2FArticle%2Fdetail%2F398675%3FcontextCategoryId%3D2695%26ref%3D25 Dublin, CA—Carl Zeiss Meditec is donating a Visante OCT to the National Eye Bank Center for evaluating corneal tissue for transplant surgery. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=3157121 Mon, 15 Jan 2007 00:00:00 +0100 3157121 Conjunctival PAM uncommon but important disease http://www.medworm.com/index.php?rid=2932931&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FNews%2FConjunctival-PAM-uncommon-but-important-disease%2FArticleStandard%2FArticle%2Fdetail%2F398673%3FcontextCategoryId%3D2695%26ref%3D25 Las Vegas—Primary acquired melanosis (PAM) of the conjunctiva is an uncommon but important disease. Although some studies have suggested that it occurs in as much as one-third of the population, most cases do not need treatment. The disease is potentially malignant, however, and arguments can be made for early treatment if risk factors are present, said Jerry A. Shields, MD, in his delivery of the Lorenz E. Zimmerman Lecture here at a combined meeting of the American Academy of Ophthalmology and the American Association of Ocular Pathologists. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2932931 Mon, 15 Jan 2007 00:00:00 +0100 2932931 Laser manufacturers announce mergers http://www.medworm.com/index.php?rid=2728601&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FLaser-manufacturers-announce-mergers%2FArticleStandard%2FArticle%2Fdetail%2F398674%3FcontextCategoryId%3D2695%26ref%3D25 Adelaide, Australia—Ellex Medical Lasers Ltd., which designs and manufactures ophthalmic laser systems, has acquired Innovative Imaging Inc., a manufacturer of ophthalmic diagnostic ultrasound systems. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2728601 Mon, 15 Jan 2007 00:00:00 +0100 2728601 AMO acquires IntraLase http://www.medworm.com/index.php?rid=2728600&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FNews%2FAMO-acquires-IntraLase%2FArticleStandard%2FArticle%2Fdetail%2F398671%3FcontextCategoryId%3D2695%26ref%3D25 The acquisition of IntraLase Corp. by Advanced Medical Optics (AMO), announced Jan. 9, joins two of the strongest performers in the refractive surgery market. The $808 million cash transaction may be the impetus for a change in how the traditional microkeratome is viewed among refractive surgeons. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2728600 Mon, 15 Jan 2007 00:00:00 +0100 2728600 Novel AMD drug being tested on 15 patients http://www.medworm.com/index.php?rid=2686638&cid=s_32305_30_f&fid=32305&url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FOphthalmic%2BNews%2FNovel-AMD-drug-being-tested-on-15-patients%2FArticleStandard%2FArticle%2Fdetail%2F398676%3FcontextCategoryId%3D2695%26ref%3D25 Redwood City, CA—The first of 15 patients has received CGC-11047, a novel poly-amine analog that targets choroidal neovascularization associated with age-related macular degeneration. (Source: Ophthalmology Times - Ophthalmic News) Ophthalmology Times - Ophthalmic News journals http://www.medworm.com/rss/comments.php?id=2686638 Mon, 15 Jan 2007 00:00:00 +0100 2686638